N6-Methyladenosine (m6A)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma

Yang Zhou; Xuhui Guan; Shuncong Wang; Huanhuan Sun; Haiqing Ma

doi:10.1155/2022/5240611

N6-Methyladenosine (m⁶A)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma

J Oncol. 2022 Sep 2:2022:5240611. doi: 10.1155/2022/5240611. eCollection 2022.

Authors

Yang Zhou^{1

2}, Xuhui Guan^{1

2}, Shuncong Wang³, Huanhuan Sun², Haiqing Ma^{1

2}

Affiliations

¹ School of Medicine, South China University of Technology, Guangzhou 510006, China.
² Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
³ KU Leuven, Biomedical Group, Campus Gasthuisberg, Leuven 3000, Belgium.

Abstract

Background: Despite increasing understanding of m⁶A-related lncRNAs in lung cancer, the role of m⁶A-related lncRNAs in the prognosis and treatment of lung squamous cell carcinoma is poorly understood to date. Thus, the current study aims to elucidate its role and build a model to predict the prognosis of LUSC patients.

Materials and methods: The data of the current study were accessed from the TCGA database. Pearson correlation analysis was performed to identify lncRNAs correlated to m⁶A. Next, an m⁶A-related lncRNAs risk model was built using a single factor, least absolute association, selection operator, and multivariate Cox regression analysis.

Results: The relevance between 23 m⁶A genes and 14,056 lncRNAs is shown by Pearson correlation analysis by Sankey diagram. Multivariate Cox regression analysis determined that 11 m⁶A-lncRNAs show predictive potential in prognosis, which is confirmed by the consistency index, Kaplan-Meier analysis, principal component analysis, and ROC curve. Additionally, the immune analysis showed that the enrichment of immune cells, major histocompatibility complex molecules, and immune checkpoints in the high and low-risk subgroups were markedly disparate, with the high-risk group showing a stronger immune escape ability and a worse response to immunotherapy.

Conclusion: In conclusion, the risk model based on m⁶A-related lncRNAs showed great promise in predicting the prognosis and the efficacy of immunotherapy.